ALK and non-Hodgkin lymphoma: Ensartinib in treating patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic disorders with ALK or ROS1 Genomic alterations (A Pediatric MATCH Treatment Trial)